Stockscreener 앱 받기
5.025
5.04%
-0.275
Cingulate Inc 주식(CING)의 최신 뉴스
Cingulate, Inc. Warrant 2021-03.12.26 on Cingulate Financial Disclosures & SEC Filings - TradingView
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits
Cingulate Inc.(NasdaqCM: CING) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Cingulate Inc.(NasdaqCM: CING) added to Russell 3000E Growth Benchmark - marketscreener.com
Cingulate Inc.(NasdaqCM: CING) added to Russell Microcap Index - marketscreener.com
Cingulate Inc.(NasdaqCM: CING) added to Russell 3000E Index - marketscreener.com
Cingulate, Inc. Actuals & Estimates (NASDAQ:CING) - TradingView
CING Forecast — Price Target — Prediction for 2027 - TradingView
Cingulate Inc (CINGW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CING Stock Price, Quote & Chart - ChartMill
Cingulate Inc (CINGW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cingulate Inc (CINGW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cingulate Inc (CINGW) Institutional Confidence - TradingKey
Cingulate Inc (CINGW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cingulate Inc (CINGW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cingulate Inc (CING) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cingulate Inc (CING) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cingulate Inc (CING) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cingulate Inc (CING) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cingulate Inc (CING) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cingulate Inc (CING) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cingulate Inc (CING) Institutional Confidence - TradingKey
Cingulate Inc (CING) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cingulate Inc (CING) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cingulate Inc (CINGW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cingulate Inc (CINGW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cingulate Inc (CINGW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 - markets.businessinsider.com
Cingulate Secures First U.S. Patent for CTx-1301 ADHD Drug, Extending Exclusivity to 2042 - Minichart
Cingulate issued U.S. patent for CTx-1301, exclusivity extended into Dec 2042 - TradingView
US patent extends Cingulate (NASDAQ: CING) CTx-1301 ADHD exclusivity - Stock Titan
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday - Sahm
Cingulate director Hargroves buys $490,271 of common stock By Investing.com - Investing.com India
CING Q1 2026 Earnings: Wider-than-expected loss as pre-revenue biotech continues pipeline development - newsline.com
Insider Makes Bold Move With Major Cingulate Inc. Stock Purchase - TipRanks
CING Maintained by Ascendiant Capital -- Price Target Lowered to $52 - GuruFocus
Cingulate director Hargroves buys $490,271 of common stock - Investing.com
Cingulate (CING) director-linked LLC buys shares, warrants as options granted - Stock Titan
Cingulate (CING) director reports initial share and warrant holdings - Stock Titan
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (NASDAQ: CING) Following FDA Complete Response Letter - citybuzz -
FDA focuses on manufacturing for Cingulate CTx-1301, not safety - Stock Titan
FDA slaps CRL on Cingulate’s CTx-1301 NDA - The Pharma Letter
Roth MKM Maintains Cingulate(CING.US) With Buy Rating, Maintains Target Price $10 - Moomoo
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301 - AJMC
Biopharma bites: FDA rebuffs Cingulate's ADHD hopeful, plus Contraline's male contraceptive funding - FirstWord Pharma
FDA Issues Complete Response Letter for Cingulate ADHD Drug CTx-1301 - Patient Care Online
FDA rejects Cingulate's application for ADHD medicine - The Business Journals
FDA Sends Complete Response Letter for Cingulate's CTx-1301 | PharmExec - PharmExec.com
FDA Issues CRL for CTx-1301 in ADHD Over CMC Concerns - HCPLive
Cingulate Gets FDA Request for Updates on ADHD Drug Application - Moomoo
Cingulate Inc - Reuters
Cingulate Inc. Q1 2026 Earnings: Wider-than-Expected Loss, Yet Shares Rally 19%Earnings Preview - thelegaladvocate.com
0.82%
0.85%
자본화:
|
볼륨(24시간):